|D000066553||Problem Behavior NIH||0.33|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
In December 2019, viral pneumonia (Covid-19) caused by a novel beta-coronavirus (SARS-CoV-2) broke out in Wuhan, China. Some patients rapidly progressed and suffered severe acute respiratory failure and died, making it imperative to develop a safe and effective vaccine to treat and prevent severe Covid-19 pneumonia. Based on detailed analysis of the viral genome and search for potential immunogenic targets, a synthetic minigene has been engineered based on conserved domains of the viral structural proteins and a polyprotein protease. The infection of Covid-19 is mediated through binding of the Spike protein to the ACEII receptor, and the viral replication depends on molecular mechanisms of all of these viral proteins. This trial proposes to develop universal vaccine and test innovative Covid-19 minigenes engineered based on multiple viral genes, using an efficient lentiviral vector system (NHP/TYF) to express viral proteins and immune modulatory genes to modify artificial antigen presenting cells (aAPC) and to activate T cells. In this study, the safety and immune reactivity of this aAPC vaccine will be investigated.
Description: Frequency of vaccine events such as fever, rash, and abnormal heart function.Measure: Frequency of vaccine events Time: Measured from Day 0 through Day 28
Description: Frequency of serious vaccine eventsMeasure: Frequency of serious vaccine events Time: Measured from Day 0 through Day 28
Description: Number of deaths during study follow-upMeasure: 28-day mortality Time: Measured from Day 0 through Day 28
Description: Duration of mechanical ventilation use in days. Multiple mechanical ventilation durations are summed upMeasure: Duration of mechanical ventilation if applicable Time: Measured from Day 0 through Day 28
Description: Proportion of patients in each category of the 7-point scale, the 7-category ordinal scale that ranges from 1 (discharged with normal activity) to 7 (death)Measure: Proportion of patients in each category of the 7-point scale Time: 7,14 and 28 days after randomization
Description: Proportion of patients with different inflammation factors in normalization rangeMeasure: Proportion of patients with normalized inflammation factors Time: 7 and 14 days after randomization
Description: A decline of 2 points on the 7-point scale from admission means better outcome. The 7-category ordinal scale that ranges from 1 (discharged with normal activity) to 7 (death)Measure: Clinical improvement based on the 7-point scale if applicable Time: 28 days after randomization
Description: Murray lung injury score decrease more than one point means better outcome. The Murray scoring system range from 0 to 4 according to the severity of the conditionMeasure: Lower Murray lung injury score if applicable Time: 7 days after randomization
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports